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ness (RBE) relative to gammas in the LSS is developed based on an older dataset with less follow-up
time. Since both risk quantities are based on uncertain quantities, such as survival curves, and REIC
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A B S T R A C T   
The risk assessment quantities called lifetime attributable risk (LAR) and risk of exposure-induced cancer (REIC) 
are used to calculate the cumulative cancer incidence risks for astronauts, attributable to radiation exposure 
accumulated during long term lunar and Mars missions. These risk quantities are based on the most recently 
published epidemiological data on the Life Span Study (LSS) of Japanese A-bomb survivors, who were exposed to 
γ-rays and neutrons. In order to analyze the impact of a different neutron RBE on the risk quantities, a model for 
the neutron relative biological effectiveness (RBE) relative to gammas in the LSS is developed based on an older 
dataset with less follow-up time. Since both risk quantities are based on uncertain quantities, such as survival 
curves, and REIC includes deterministic radiation induced non-cancer mortality risks, modelled with data based 
on the general population, the risks for astronauts may not be optimally estimated. The suitability of these risk 
assessment measures for the use of cancer risk calculation for astronauts is discussed. The work presented here 
shows that the use of a higher neutron RBE than the value of 10, traditionally used in the LSS risk models, can 
reduce the risks up to almost 50%. Additionally, including an excess absolute risk (EAR) baseline scaling also 
increases the risks by between 0.4% and 8.1% for the space missions considered in this study. Using just an EAR 
model instead of an equally weighted EAR and excess relative risk (ERR) model can decrease the cumulative 
risks for the considered missions by between 0.4% and 4.1% if no EAR baseline scaling is applied. If EAR baseline 
scaling is included, the calculated risks with the EAR- and the mixed model, as well as the risks calculated with 
just the ERR model are almost identical and only small differences in the uncertainties are visible.   
1. Introduction 
A good understanding of radiation related detrimental health effects 
and risk levels is important when planning manned missions into space 
for either routine or exploratory purposes. Currently different national 
space agencies set individual limits on either risks or radiation doses, 
such that mission radiation related risks remain within a predefined 
acceptable range. A major limiting factor for long-term manned mis-
sions is space radiation from galactic cosmic rays (GCR) and from solar 
particle events (SPE). The GCR can originate outside the solar system or 
from solar winds and are made up of protons and charged nuclei in the 
energy range between 1 MeV and 10 GeV. The SPE consist mainly of 
protons with kinetic energies below 1 MeV up to a few hundred MeV 
which are emitted by the sun 5 to 10 times a year. According to  
Cucinotta et al. (2010) only less than 10% of the SPE would lead to 
significant health risks for non-protected astronauts, but the occurrence 
of a SPE cannot be predicted, only detected after the event. The SPE and 
GCR with energies below 2 GeV are modulated by an eleven-year solar 
cycle. At solar minimum the solar wind is weakest and the GCR flux is 
twice as high as at solar maximum. Due to this radiation, an astronaut 
could be exposed to a total effective dose of more than 1 Sv on a 500- 
day Mars mission (Shiver, 2008), if radiation protection is neglected. 
Therefore, risk modeling at doses larger than 1 Gy is important for 
providing realistic risk estimations for long term exploratory space 
missions. Currently two main cumulative risk quantities are generally 
applied for producing radiation related cancer risk estimations. The first 
quantity, called lifetime attributable risk (LAR), was introduced by  
Vaeth and Pierce (1990) and is an integration of failure rates (cancer 
incidence rates in this study) based on the conditional survival prob-
ability of a person alive at age at exposure e, to reach at least an at-
tained age a. The survival curves, required in the calculations of LAR, 
refer to unexposed populations. This feature makes the LAR for cancer 
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independent of non-cancer excess mortality, where this latter quantity 
has very large uncertainties. Walsh et al. (2014) noted that the LAR can 
be used to calculate future cancer risks, but large uncertainties could 
arise from the assumption that the baseline cancer rates used in the 
calculation will still be representative for the future population. A 
second cumulative risk measure introduced by Vaeth and Pierce (1990), 
is the risk of exposure-induced cancer (REIC). REIC is similar to LAR, 
except that in the calculation of REIC, survival curves for populations 
exposed to a dose D are used. Difficulties arise in the specification of a 
dose dependent survival curve which includes acute mortality after an 
exposure to several Gy as well as a late radiation induced non-cancer 
mortality (Kellerer et al., 2001). 
In the German software tool ProZES documentation 
(Ulanowski et al., 2020) it is explained that, in order to obtain the ra-
diation attributed cancer risk for a population of interest (European 
astronauts in this study), a transfer needs to be applied to the risk ob-
tained from the studied population (The Life Span Study (LSS) of Ja-
panese A-bomb survivors). In general, the excess risk calculation, which 
is required in the calculation of cumulative risks, can be represented as 
the weighted sum of the excess absolute risk (EAR) and the excess re-
lative risk (ERR) multiplied with the age and gender specific cancer 
incidence rates in the population and year of interest. Consequently, a 
scaling to the LSS EAR can be applied in order to increase the degree of 
representativeness of EAR to the European astronauts. In this study an 
EAR baseline scaling, based on the ratio of the baselines between the 
target and study population, is applied. It is important to note that the 
differences in the baseline risks are due to national and ethnic factors as 
well as due to differences in secular trends. In this study, space radia-
tion risk calculations with and without EAR scaling are presented and 
discussed. 
The ICRP (2007) used weights of 0.5 in order to weight the ERR and 
EAR models for all tissues in the calculation, except for breast and bone 
marrow, where only an EAR model was applied. Since the exact value 
of these weights is still under discussion, the cancer incidence risks are 
calculated in three different ways in this study: just an EAR model, an 
equally weighted risk model and just an ERR model, to reflect the full 
range in the uncertainty connected with the choice of EAR and ERR 
model weightings. 
In order to transfer solid cancer risks obtained for A-bomb survivors 
LSS at high dose-rates to low dose-rates the dose and dose-rate effec-
tiveness factor (DDREF) is included in the solid cancer risk models. The  
ICRP (2007) recommended a DDREF value of 2, but recent studies, 
combining direct evidence from many epidemiological studies with a 
meta-analytic approach (Hoel, 2018; Jacob et al., 2009; Kocher et al., 
2018; Shore et al., 2017), have indicated that a value of less than 2 
could be more appropriate than 2. Therefore, in this study space ra-
diation risks are calculated with a DDREF of 1. 
In the most recent publicly available LSS epidemiological data from 
the Radiation Effects Research foundation (RERF), website: www.rerf. 
or.jp, pertaining to solid cancer and leukemia incidence, no information 
on separate neutron and gamma doses are published. Only the total 
colon dose including the relative biological effectiveness (RBE) 
weighted neutron dose is considered. Since the neutron RBE is energy 
and dose dependent, a fixed RBE of 10 can easily lead to an over-
estimation of the risk per unit dose. Therefore, in this study an RBE 
model is developed based on an older LSS dataset from the RERF with 
less years of follow-up, but where γ- and neutron doses are published 
separately. This model is then applied to the most recent dataset in 
order to analyze the impact of the neutron RBE on space radiation 
protection. 
The excess relative (ERR) and absolute (EAR) incidence risks for 
solid cancer per unit colon dose and leukemia per unit red bone marrow 
(RBM) dose, which are used to calculate the cumulative risks presented 
here, are fitted to the atomic bomb survivors LSS data from Hiroshima 
and Nagasaki for the relevant dose range. Using the same LSS data, the 












































































































































































































































































































































































L. Hafner, et al.   Life Sciences in Space Research xxx (xxxx) xxx–xxx
2
calculated. An empirical neutron RBE model is applied in order to 
analyze the influence of a different neutron RBE on risk and the impact 
of using different risk models and the EAR baseline scaling on the two 
cumulative risk quantities considered here (LAR and REIC). Finally, 
cancer incidence risks for a lunar and two Mars missions are estimated 
with LAR and REIC including a comprehensive Monte-Carlo simulation 
of uncertainties, using the most recent publicly available epidemiolo-
gical data from the RERF. 
2. Materials and methods 
2.1. Atomic-bomb survivors data 
Different publicly available LSS epidemiological data from the 
Radiation Effects Research foundation (RERF), website: www.rerf.or.jp, 
pertaining to solid cancer (Grant et al., 2017; Preston et al., 2007) and 
leukemia (Hsu et al., 2013) incidence with either DS02 or DS02R1 
doses are analysed. The different datasets are listed in Table 1. For the 
dataset 1 (Grant et al., 2017) which contains 22,538 first primary solid 
cancers among 105,444 people with 3.8 person years of follow-up, only 
the RBE=10 weighted neutron dose information is given. Dataset 2 
(Preston et al., 2007) has 17,448 first primary solid cancers among 
105,427 people with 2.8 million person years of follow-up and dataset 3 
(Hsu et al., 2013) contains 312 leukemias among 113,011 people with 
3.6 million person years of follow-up. In dataset 2 different types of 
organ doses are available and in datasets 2 and 3 the RBE=10 weighted 
colon and RBM doses as well as separate γ- and neutron doses are 
published. Computations based on dataset 1 for solid cancer risks are 
performed with respect to the weighted colon doses while computations 
based on dataset 3 for leukemia risks are based on the weighted RBM 
doses. 
2.2. ERR and EAR risk models 
The mathematical forms of the ERR and EAR models applied in this 
paper are the same as those considered by Schneider and Walsh (2009). 
The differences between Schneider and Walsh (2009) and the present 
work are that the most recent LSS incidence data are considered instead 
of LSS mortality data and that, in order to analyze the impact of the 
neutron RBE, an empirical model, based on the older dataset 2, is used. 
To characterize the radiation related solid cancer incidence risk, a 
linear excess risk (ER - where ER is either ERR or EAR) model is con-
sidered and fitted to the data of dataset 1. The risks are factorized into a 
function of colon dose Dc and a modifying function that depends on the 
variables attained age a, age at exposure e and gender s. 
=ER D e a s D µ e a s( , , , ) ( , , )s c c s (1) 
where β is the initial slope. The subscript S denotes solid cancer and μs is 
the risk effect modifying function: 
= +µ e a s
e a






s e a (2) 
where - is used for males and + for females. The fit parameters γe, γa 
and s are gender-averaged and centered at an attained age a of 70 years 
and an age at exposure e of 30 years. 
The leukemia incidence excess relative and absolute risks are tra-
ditionally fitted to a linear-quadratic dose response model (Hsu et al., 
2013), using dataset 3: 
= +ERR D e a s D D µ e a( , , , ) ( ) ( , )L m m m L
2
1 (3)  
= +EAR D e a s D D µ e a s( , , , ) ( ) ( , , )L m m m L
2
2 (4) 
where β and δ are the linear and quadratic dose-response parameters. L 
denotes leukemia, Dm red bone marrow dose and μL1 and μL2 are the risk 
effect modifying functions: 
= +µ e a log
a e a
( , ) exp
40
log
70L e a1 (5)  
= +µ e a s
e a





exp( )L e a2 (6)  
The fit parameters γe and γa are gender-averaged and centered at an 
attained age a of 70 years and an age at exposure e of 30 years. The fit 
parameter s is given for women and set to 0 for men. 
2.3. Neutron RBE model 
In the most recent dataset 1, with the most years of follow-up, only 
the total colon doses, including the RBE=10 weighted neutron dose, 
are available and no separate information about neutron and gamma 
doses are published. In order to analyze the influence of different 
neutron RBEs on cancer risk estimation, a neutron RBE model based on 
the older dataset 2, where separate neutron and gamma doses were 
available, is developed. Therefore, the ERR and EAR models for solid 
cancer and leukemia shown in the Appendix A are fitted with respect to 
organ averaged dose to the A-bomb survivor data for six different 
neutron RBEs: 10, 35, 60, 80, 100 and the dose dependent RBE from  
Sasaki et al. (2006). The resulting fit parameters are shown in the Ap-
pendix B in Tables B1–B4. 
In order to fit the risks as function of RBE, the mean neutron dose 
weighted RBE, calculated from the dose dependent RBE from  
Sasaki et al. (2006), needs to be determined using the neutron RBM 













person years denotes the neutron dose for each cell in the grouped 
LSS data, Dn
tot the total neutron dose of all cells in the grouped publicly 
available A-bomb LSS data and the neutron dose dependent RBE is 















with the crossover dose ϑ: 
=
(9)  
The kerma-weighted α-coefficient for γ-rays at 5 cm depth is 
1.549 × 10−2Gy−1 and for neutrons it is 119.334 × 10−2Gy−1. The β- 
coefficient is 5.355 × 10−2/Gy for both neutrons and γ-rays. With this 
method the mean neutron dose weighted RBE from Sasaki is found to be 
25 from dataset 2. 
The neutron RBE model is fitted separately for solid cancers fS and 
leukemia fL1/L2 : 
=ER D e a s RBE ER D e a s f RBE( , , , , ) ( , , , ) ( )s c s c S (10)  




Where ERs(Dc, e, a, s) is the excess risks from Eq. (1) and μL1/L2(e, a) are 
the risk effect modifying functions of Eqs. (5) and (6). Since the fit 
parameters for the attained age, age at exposure and gender risk effect 
modifiers obtained with dataset 2 for solid cancer and dataset 3 for 
leukemia, shown in the Appendix B in Tables B1–B4, only vary slightly 
with RBE, they are assumed to be constant and the values for RBE=10 
are used for the modeling. The ratios of the main risk to dose response 
fit parameters (e.g., the β in Eq. (1))) at different RBEs to the risk to 
dose response fit parameter of RBE=10 for solid cancer and leukemia 
at 1 Gy, shown in the Appendix B in Tables B1–B4, are then plotted as a 
function of RBE and the uncertainties are calculated with a Gaussian 
error propagation using the individual fit parameter variances shown in  
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Table 2. Then two different models are considered to fit the data points. 
For solid cancer and leukemia, a linear model is considered for the 
excess risk: 
= +f RBE RBE( ) ( 10) 1S L/ (12) 
as well as an exponential approach for solid cancer: 
=f RBE RBE( ) exp( ( 10))S (13)  
And for leukemia: 
=f RBE RBE( ) exp( ( 10) )L
2 (14) 
where α denotes the fit parameter, the subscripts S and L denote solid 
cancer and leukemia respectively. 
2.4. LAR 
The method of Kellerer et al. (2001) is applied here to obtain LAR: 
= +
+ +
LAR e h a e D
S a
S e
da h a e D
S a
S e
da( ) ( , , )
( )
( )










where a denotes the attained age, e the exposed age and l the minimum 
latency period (5 years for solid cancer, 2 years for leukemia). The 
excess cancer incidence risk for solid cancer can be written as: 
=
+
h a e D
w ERR D a e m a w EAR D a e
DDREF
( , , )
( , , ) ( ) ( , , )/10, 000
S
S S S S S1 2
(16) 
while for leukemia the excess cancer incidence risk is given by: 
= +h a e D w ERR D a e m a
w EAR D a e
( , , ) ( , , ) ( )
( , , )
10, 000





where mS(a) and mL(a) are the baseline cancer incidence rates from 
Germany for solid cancer and leukemia respectively, used to be re-
presentative for European astronauts. The rates are calculated by taking 
the mean of the incidence rates from the website www.krebsliga.de 
from 2010 to 2016. The ERR and EAR are the excess relative and ab-
solute risks from Eqs. (1), (3) and (4). The fit parameters of the EAR 
were calculated per 10,000 PY Gy, which is accounted for by the factor 
10,000 in the Eqs.(16) and (17). For solid cancer, the excess risks are 
weighted with the weights wS1 and wS2 and for leukemia with the 
weights wL1 and wL2. S(a) is the survival curve from  
Kellerer et al. (2001) for the unexposed population: 
=S a c c a( ) exp( (1 exp( )))1 2 (18) 
with c1=0.0015, c2= 0.0820 for males and c1=0.0005, c2= 0.0905 for 
females. The ratio of the two survival curves in Eq. (15) describes the 
conditional probability of a person to reach at least age a when having 
been alive at age e. In this study all cumulative risks are calculated up to 
an attained age a of 89 years. 
2.5. REIC 
To obtain REIC the method to calculate the risk of exposure induced 
death (REID) from Schneider and Walsh (2009), which is based on the 
methods introduced by Kellerer et al. (2001), is applied with the 
adaptation to calculate cancer incidence instead of mortality: 
= +
+ +
REIC e D h a e D
S a D
S e D
da h a e D
S a D
S e D
da( , ) ( , , )
( , )
( , )










where hS and hL are the excess cancer incidence risks for solid cancer  
Eq. (16) and leukemia Eq. (17) respectively. The attained age in years is 
denoted by a, e is the age at exposure in years, l the minimum latency 
period. The ratio of the survival curves of the population after an ex-











(1 ( ))(1 ( ))
(20) 
where S(a) is the survival curve of the unexposed population from  
Eq. (18). The NCM(D) is the excess relative non-cancer mortality. It 
accounts for late radiation induced non-cancer mortality, such as car-
diac mortality for doses higher than 0.5 Gy. For each Gy a factor of 0.1 
is added to the quantity. From Anno et al. (2003) the acute radiation- 













where k accounts for the application of medical care. If no medical care 
is applied k=−4.4011 and if medical care is applied k=−5.6571. In 
this study only results for no medical care are presented and discussed. 
2.6. Dose scale 
Computations of solid cancer risk are based on the weighted colon 
dose, while the computations of leukemia risks are performed with 
respect to the weighted RBM dose. Since the energies of space radiation 
are very high, one can assume that the colon and the RBM doses will be 
equal for a given fluence at first order. Therefore, in this study, the total 
cancer risk is calculated by simply adding up the calculated solid cancer 
and leukemia risks. 
2.7. EAR baseline scaling 
In order to obtain the radiation attributed cancer risk for European 
astronauts a transfer needs to be applied to the risk obtained for the 
studied population of Japanese A-bomb survivors (Ulanowski et al., 
2020) since the Japanese baseline at calendar = +year e a1945
may not be representative of the baseline for European astronauts in 
2020, due to, among other factors, secular trends and racial differences 
in cancer rates. Here this transfer is realized by an EAR baseline scaling 
as described by Ulanowski et al. (2020) where the ratio of the baseline 
incidence rates of Germany m(a)G and Japan m(a)J is used as a scaling 
factor: 
=EAR D e a s EAR D e a s
m a
m a





J (22)  
The internal baseline from the LSS cohort of A-bomb survivors in 
Japan has a major contribution from the first dose group of 1–5 mGy in 
the epidemiological data. This baseline yields uncertainties, because a 
few of the cancers in this group could be radiation related excess, but it 
is not known which ones. Therefore, the ratio of the excess absolute risk 
and the excess relative risk is used to define the internal baseline from 
the LSS cohort of A-bomb survivors in Japan in this study: 
Table 2 
Results of fitting a linear and an exponential model for solid cancer and a 
quadratic exponential model for leukemia to the ratio of the risk to dose re-
sponse fit parameters in Tables B1–B4 shown in the Appendix B and the risk to 
dose response fit parameter for neutron RBE=10. For leukemia only the results 
for the quadratic dose term are shown, since for the linear dose term no neutron 
RBE dependence was found.     
Linear model  
Risk Solid cancer Leukemia 
ERR −0.0060   ±   0.0003 −0.0136   ±   0.0017 
EAR −0.0059   ±   0.0003 −0.0133   ±   0.0016 
Exponential model 
Risk Solid cancer Leukemia 
ERR −0.0079   ±   0.0002 −0.0014   ±   0.0003 
EAR −0.0077   ±   0.0002 −0.0012   ±   0.0002 
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=
EAR D e a s
ERR D e a s
m a
( , , , )




In order to estimate the uncertainties on the LAR and REIC central 
estimates, Monte Carlo simulations are used to provide appropriate 
confidence intervals on the central estimates. The uncertainties of the 
fit parameters (for the dose-response and the risk effect modifiers) are 
included by Monte-Carlo sampling involving 1000 realisations of these 
parameters according to the corresponding elements of the parameter 
covariance matrix. The uncertainties of the German baseline incidence 
rates are assumed to be Poisson distributed, and also sampled accord-
ingly, with 1000 realisations. From the combined simulations the 95% 
confidence interval is considered to represent the uncertainty. Since no 
uncertainties were given with the published fit-parameters for the NCM 
and ARM models, these uncertainties could not be accounted for in the 
Monte-Carlo treatment of uncertainties. 
3. Results 
3.1. Neutron RBE model 
In Fig. 1 the ratios of the dose fit parameter at RBE 10, 25, 35, 60, 80 
and 100 and the dose fit parameter at neutron RBE 10 are shown with 
the different fits from Eqs. (12) to (14). The model fit parameters are 
listed in Table 2. Due to the large uncertainty in the model parameters 
the ratio of the linear dose parameter for solid cancer and the ratio of 
the quadratic dose parameter for leukemia, can be fitted with the linear 
model as well as with the exponential model. Since the exponential 
model fits the data slightly better and it will not take negative values for 
even higher RBE values, the further analysis is executed with this 
model. The linear dose-response parameter β for leukemia does not 
show any RBE dependence for both excess risks. Consequently, no 
model is applied. 
3.2. ERR and EAR risk models 
Fitting the ERR and EAR models Eqs. (1)–(4) to the Japanese atomic 
bomb survivor data yields the model fit parameters in Tables B6 and B7 
and the corresponding covariance matrices in Tables B8–B11 shown in  
Appendix B. In Fig. 2 LAR and REIC are calculated with an equally 
weighted excess risk model as a function of dose with and without EAR 
scaling for men, using a neutron RBE of 10 and an exposed age of 41 
years. The 95% confidence interval is also calculated and shown by 
dashed lines. In Fig. C1 in the Appendix C the results for the same set up 
are shown for women. LAR and REIC increase both with dose and 
women have in general a higher cancer incidence risk than men. Using 
the equally weighted excess risk model and no EAR baseline scaling 
women exposed to 1 Gy at age 41 years have a 4.7% higher LAR and a 
4.3% higher REIC than men. Including EAR scaling the LAR for women 
rises by 3.7% and the REIC by 3.3% compared to no scaling and for men 
the LAR with the scaled EAR is 2.8% higher than without, while REIC 
increases by 2.6%. In Fig. 2 the neutron RBE-dependence of LAR and 
REIC for the different scenarios of EAR scaling for men and in Fig. C1 
the results for women are shown. The results are calculated for an ex-
posure of 1 Gy at an age of 41 years using the developed neutron RBE 
model and the equally weighted excess risk model. Both risks decrease 
with increasing neutron RBE. Using a RBE of 100 instead of 10 de-
creases the risks by almost 50%. Additionally, the results for LAR and 
REIC for every scenario of EAR scaling for an exposure of 1 Gy colon 
dose and a neutron RBE of 10 as function of exposed age for men is 
shown in Fig. 2 and for women in Fig. C1. Both risks decrease with 
increasing age at exposure. In Fig. 3 REIC and LAR are calculated with 
an EAR model as function of dose, neutron RBE and exposed age for 
men and in Fig. 4 the risk estimations are shown, calculated with an 
ERR model. The equivalent figures for women Figs. C2 and C3 can be 
found in the Appendix C. Using the ERR model the EAR scaling cannot 
be applied. The results calculated including EAR scaling with the EAR 
model and the equally weighted excess risk model and the ERR results 
are almost equivalent and show only small differences in the un-
certainties. For men, LAR without EAR scaling is 2.8% smaller calcu-
lated with the EAR model than calculated with the equally weighted 
model and 3.7% smaller for women. For REIC the risks decrease by 
2.5% and 3.3% for men and women respectively. 
4. Discussion 
4.1. Neutron RBE 
Different studies found indications that the neutron RBE for A-bomb 
survivors is higher than the traditionally used RBE of 10.  
Kellerer et al. (2006) analysed the LSS data and estimated the neutron 
RBE to be 100. Rühm and Walsh (2007) calculated the RBE according to 
the ICRP 60 recommendations and found it to be 40.2 at 500 m and 
25.1 at 2000 m distance to the epicenter. Satoh et al. (2018) evaluated 
the log-likelihood at several RBE values in the range of 5–120 for A- 
bomb survivors from Hiroshima and from the LSS (Hiroshima and 
Nagasaki) separately and found the values 65 and 75 respectively.  
Walsh (2013) applied a hierarchical partitioning approach to calculate 
a neutron RBE directly from the LSS all solid cancer ERR fit parameters 
per unit colon dose and reported an RBE of 65 (95% CI: 11; 170). 
Applying a similar approach to Walsh (2013) but with more recent 
data, Cordova and Cullings (2019) calculated different RBEs for dif-
ferent organs based on the LSS data. The RBE for colon dose was found 
to be 80 and for other types of organ doses, between 25 and 60. Ad-
ditionally, Cordova and Cullings (2019) agreed with previous state-
ments in Kellerer et al. (2006) by stating that since the colon is among 
the deepest of organs it may not be the best organ dose type to use for 
the RBE estimations, since colon doses minimize the role of neutrons 
due to the high body shielding of the colon. Using a higher neutron RBE 
than the fixed RBE of 10 has a huge impact on the risk estimates. For an 
exposure of 1 Gy at an age of 41 years using a neutron RBE of 10, 
equally weighted excess risks and no EAR baseline scaling, LAR for a 
woman is 16.2% (13.7; 19.0) and REIC is 14.6% (12.3; 17.1). For men 
the risks are 11.5% (9.4; 14.0) and 10.3% (8.4; 12.6) respectively. If a 
neutron RBE of 80 is used the risks decrease for women to 9.2% (7.6; 
10.9) and 8.3% (6.8; 9.8) for LAR and REIC respectively and for men to 
6.4% (4.9; 8.0) and 5.7% (4.4; 7.2). Consequently, the risks decrease by 
almost 50% for a higher neutron RBE. However, it has to be noted that 
the RBE dependence in this study is calculated with an empirical neu-
tron RBE model, ideally the separate neutron and gamma doses for a 
selection of organs are required with all the publically available LSS 
data. 
4.2. EAR baseline scaling 
The EAR baseline scaling described by Ulanowski et al. (2020) is 
included in this study in order to transfer the risks obtained for the 
studied population (Japanese A-bomb survivors) to European astro-
nauts. Using the scaled EAR has a strong impact on the space radiation 
risk calculation. For the missions considered in this study, the doses are 
in the cSv range and the maximum increase of the cancer risk due to 
scaling is 8.1%. In Figs. 2 and 3 a dose dependence can be observed. For 
LAR the difference increases with dose while for REIC the largest dif-
ference can be found in the dose range from 1 to 3.5 Gy. With regard to 
possible long-term exploratory space missions in the future, where as-
tronauts are exposed to higher doses, the impact of the EAR baseline 
scaling needs to be considered. 
Nevertheless, it has to be noted that the use of such a scaling is still 
being discussed, because on the one hand it is not clear whether the 
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transfer of the absolute radiation induced cancer risk between two 
populations can be described by considering the differences in the 
baseline of these populations, since the origin of these risks are dif-
ferent. Baseline cancer incidence rate differences are due to environ-
mental influences and lifestyle choices, while for the excess absolute 
risk the origin of the mutations is radiation. On the other hand, the 
differences in the baselines are already taken into account in the cal-
culation by considering a weighting between relative and absolute ex-
cess risks. 
4.3. Excess risk models 
The ICRP (2007) recommended to use a 50:50 weighting for the 
excess risks to calculate the cumulative incidence risks for almost every 
cancer site. Only for breast cancer and bone marrow is a pure EAR 
model recommended. Nevertheless, there are still discussions going on 
(Walsh and Schneider, 2012; Little and Wakeford, 2012; Pawel and 
Gilbert, 2012), about which weights should be used. In this study the 
risks calculated with the 50:50 weighting of the excess risks are com-
pared to the risks calculated with the two extreme cases of applying a 
Fig. 1. The black points show the ratio of the different dose fit parameters from dataset 2 for solid cancer and dataset 3 for leukemia at different RBEs (10, 25 
(Sasaki), 35, 60, 80, 100) and the dose fit parameter at RBE=10 as function of the neutron RBE. The uncertainties are calculated with a Gaussian error propagation 
using the variances shown in the Appendix B in Table B5. The solid line shows the exponential fit and the dashed line the linear fit. All other fit parameters are 
assumed to be constant. 
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Fig. 2. Results for LAR and REIC in decimals calculated for men as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown with and without EAR baseline scaling. The risks are calculated with equally weighted excess risks. The solid line corresponds to the 
central estimate and the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival 
curves above 2 Gy, are not included in the results for REIC). 
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Fig. 3. Results for LAR and REIC in decimals calculated for men as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown with and without EAR baseline scaling. The risks are calculated with an EAR model. The solid line corresponds to the central 
estimate and the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival curves 
above 2 Gy, are not included in the results for REIC). 
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Fig. 4. Results for LAR and REIC in decimals calculated for men as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown without EAR baseline scaling. The risks are calculated with an ERR model. The solid line corresponds to the central estimate and 
the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival curves above 2 Gy, 
are not included in the results for REIC). 
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Fig. C1. Results for LAR and REIC in decimals calculated for women as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown with and without EAR baseline scaling. The risks are calculated with equally weighted excess risks. The solid line corresponds to the 
central estimate and the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival 
curves above 2 Gy, are not included in the results for REIC). 
L. Hafner, et al.   Life Sciences in Space Research xxx (xxxx) xxx–xxx
10
Fig. C2. Results for LAR and REIC in decimals calculated for women as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown with and without EAR baseline scaling. The risks are calculated with an EAR model. The solid line corresponds to the central 
estimate and the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival curves 
above 2 Gy, are not included in the results for REIC). 
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Fig. C3. Results for LAR and REIC in decimals calculated for women as function of dose, neutron RBE and exposed age for a dose of 1 Gy, a neutron RBE of 10 at an 
exposed age of 41 years are shown without EAR baseline scaling. The risks are calculated with an ERR model. The solid line corresponds to the central estimate and 
the dashed lines show the 95% confidence interval. Note: the very large uncertainties in the radiation dependant acute mortality in the survival curves above 2 Gy, 
are not included in the results for REIC). 
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pure EAR- and a pure ERR model. In the missions considered, using an 
EAR model instead of an equally weighted excess risk model leads to a 
decrease of the risk of between 0.4% and 4.1% if no EAR baseline 
scaling is applied. If EAR baseline scaling is included, the calculated 
risks with the EAR- and the equally weighted model, as well as the risks 
calculated with the ERR model are almost identical and only small 
differences in their uncertainties are visible. 
4.4. DDREF 
In this study the risks are calculated with a DDREF of 1, nevertheless 
one has to keep in mind that including a DDREF of 2 as recommended 
by the ICRP (2007) for solid cancers in the calculations would reduce 
the risk estimates for lunar and Mars missions by almost 50%. This large 
impact is mostly due to the fact that in this dose range the leukemia risk 
does not contribute much to the total risk estimation, because it rises 
almost quadratic with dose. For larger doses the impact of the DDREF 
will therefore be smaller. Direct evidence from epidemiology may be 
considered to guide the choice of which DDREF value is currently the 
most appropriate to apply. Several recent, all solid cancer meta-analysis 
studies (Hoel, 2018; Jacob et al., 2009; Kocher et al., 2018; Shore et al., 
2017), have aimed to provide such direct evidence on the magnitudes 
of a dose-rate effectiveness factor (DREF) by analyzing published risk 
results from many epidemiological studies with different dose-rates.  
Table 4 provides a summary of the DREF results from these studies. The 
first meta-analysis in Table 4 by Jacob et al. (2009) was recently up-
dated (Shore et al., 2017) to include 22 low-dose and/or low dose rate 
solid cancer studies (19 mortality studies and 3 incidence studies). 
Another analysis of the DREF was based on a much less comprehensive 
selection of studies (Kocher et al., 2018) when compared with the wider 
range of studies considered recently by Shore et al. (2017) and by  
Hoel (2018) in their assessments of the DREF. Table 4 shows that the 
evidence for DREF of 1 or 2, depends strongly on the types and numbers 
of epidemiological studies considered, with the lower values being 
obtained when one influential study (the Mayak study) was not in-
cluded in the meta-analysis estimators of DREF. The dependency on the 
included studies in the analysis has also been observed by  
Haley et al. (2015) by re-estimating the DDREF including 15 animal 
studies considering acute and protracted exposures. Including the an-
imal data, they found the DDREF to be in the range of 4.8 to infinity. 
Also, Tran and Little (2017) aimed to provide an estimate on the low- 
dose extrapolation factor (LDEF) and DREF by analysing animal data. 
They found the central estimate of the DREF for gamma exposure with 
malignant outcomes to be in the range of 1.2–2.3 and the LDEF to be 
1.2 for all solid cancers for most malignant outcomes. A LDEF of more 
than 1 was also implied by Little et al. (2020) by estimating the dose- 
response curvature for malignant outcomes, which would be consistent 
with the recommended ICRP DDREF of 2. From these results it can be 
seen that the current direct evidence from animal and epidemiological 
studies is not strong enough to confidently guide the choice of whether 
to apply a DDREF of 1 or 2. Therefore, based on the current state of 
knowledge, it is important to keep different DDREF values under con-
sideration in the astronaut cancer risk assessments. 
4.5. Cancer risk calculation methods for space missions 
In order to calculate the radiation related cancer risk, two different 
cumulative risk measures are used in this study. In the calculation of 
REIC, late radiation induced non-cancer mortality is accounted for in 
the survival curves. These deterministic non-cancer risks are modelled 
based on data of the general population, but since astronauts are very 
sportive, healthy and non smokers, they are not representative for this 
group. It can therefore be that due to their excellent physical condition, 
astronauts are less sensitive to radiation induced non-cancer health 
risks (e.g. cardiac attacks) and the deterministic risk model would be 
different for this atypical occupational group. Using nevertheless the 
models based on the general population may therefore lead to an un-
derestimation of the cancer incidence risk for astronauts at high doses. 
Since LAR does not account for late radiation induced non-cancer 
mortality it may be the more appropriate risk assessment method to 
calculate cancer incidence risks for astronauts, since it avoids a possible 
underestimation of the risk. Nevertheless, it is important to point out 
that both risk calculations are based on survival curves, either of the 
unexposed or exposed population, which are amongst the most un-
certain quantities in the calculation. Another method, particularly 
useful for risk assessments in highly atypical exposed groups such as 
astronauts (see Walsh et al., 2019a), that reduces the dependence of 
radiation related risk assessments on population statistics and survival 
curves (Ulanowski et al., 2019), has recently been published. Current 
work is underway to include a consideration of this new method 
(Ulanowski et al., 2019) into the types of analyses presented here. 
The NASA (Cucinotta et al., 2007) specified that the risk of exposure 
induced death (REID) shall not exceed 3% at the 95% upper confidence 
level. Considering the lethality factors for different cancers in Table 
A.4.5 of the ICRP 103 report (2007) and weighting them with the 
cancer case counts of the A-bomb survivor data, a lethality factor of 
0.49 can be found for all cancers. Taking this lethality factor into ac-
count, the limit for REIC and LAR can be set to be 6.1%. In Table 3 the 
radiation related cancer risks are calculated for both genders for a 180 
days lunar mission, a Mars swing-by and a Mars surface mission at solar 
minimum for different scenarios of risk models and EAR baseline 
scaling including the uncertainties. The upper 95% of the confidence 
Table 3 
Results for LAR and REIC for all cancer in% for different mission types and doses using models based on dataset 1 including the 95% CI. All results are calculated for 
an age at exposure of 40 years, a neutron RBE of 10 and a DDREF of 1.                
ERR based model Equally weighted ERR/EAR model EAR based model   
W/o EAR scaling W/o EAR scaling With EAR scaling W/o EAR scaling With EAR scaling  
Mission E/Sv LAR REIC LAR REIC LAR REIC LAR REIC LAR REIC 
Males 
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level of the cancer induction risks for a lunar mission lies, for every 
scenario, below the risk limit of 6.1%. Consequently, a half year or even 
longer space missions to the Moon are possible without exposing the 
astronauts to an intolerable risk considering radiation induced cancer 
induction. However, considering the effective doses for Mars missions, 
the risk limit of 6.1% is exceeded by far, for all risks calculated in this 
study for every scenario of risk models and EAR baseline scaling. 
Table 4 
Dose Rate Effectiveness Factor (DREF) from 4 solid cancer meta-analyses comparing low dose/low-dose-rate studies to the life span studya.    
Low dose/low-dose-rate Studies in the Comparison DREF (95% CI)  
Jacob et al. (2009) Main analysis of 7 mortality studiesb 0.83 (90% CI 0.53; 1.96) 
Shore et al. (2017) All 22 LD/LDR studies (19 mort + 3 inci)c 3.0 (1.9; 7.7) 
Shore et al. (2017) All studies, except Mayak workersc 1.9 (1.0; 11) 
Shore et al. (2017) All mortality studies, except Mayak workersc 0.9 (0.5; 2.5) 
Shore et al. (2017) All studies, but including only the Mayak workers without potential plutonium exposurec 2.0 (1.2; 6.2) 
Hoel (2018), analysis of 12 LD/LDR studiesd 2.6 (1.6; 7.1) 
Kocher et al. (2018)e 1.3 (90% CI 0.47; 3.6)  
a These comparisons used statistical modeling to match the LSS to individual low dose/low-dose-rate studies on sex, mean age at initial exposure, 
mean final attained age and dose conversion factors. 
b (Jacob et al., Occ. Env. Med (BMJ). 66, 789–96, 2009) 
c (Shore et al., Int J Radiat Biol, 93:1064–78, 2017). 
d (Hoel D, Int J Radiat Biol, 94:307–314, 2018). 
e (Kocher et al. Health Phys 114:602–622, 2018).  
Table B1 
Results of fitting a linear model to solid cancer relative incidence to the atomic 
bomb data at attained age 60 years after exposure at age 41 years applying the 
EPICURE-AMFIT code to the atomic survivor data of dataset 2 with respect to 
organ averaged dose.       
RBE β∗ γe γa s  
10 0.361 −0.202 −1.65 0.312 
35 0.288 −0.186 −1.64 0.341 
60 0.238 −0.176 −1.64 0.361 
80 0.208 −0.170 −1.63 0.373 
100 0.185 −0.165 −1.63 0.383 
Sasaki 0.320 −0.194 −1.62 0.292 
*ERR/Gy.  
Table B2 
Results of fitting a linear model to solid cancer absolute incidence to the atomic 
bomb data at attained age 60 years after exposure at age 41 years applying the 
EPICURE-AMFIT code to the atomic survivor data of dataset 2 with respect to 
organ averaged dose.       
RBE β∗ γe γa s  
10 19.3 −0.298 2.34 0.232 
35 15.5 −0.281 2.31 0.261 
60 12.8 −0.270 2.29 0.281 
80 11.2 −0.264 2.28 0.293 
100 9.99 −0.259 2.27 0.303 
Sasaki 17.1 −0.290 2.37 0.212 
*EAR per 10,000 PY Gy.  
Table B3 
Results of fitting a linear-quadratic model to leukemia relative incidence to the 
atomic bomb data at attained age 60 years after exposure at age 41 years ap-
plying the EPICURE-AMFIT code to the atomic survivor data of dataset 3 with 
respect to organ averaged dose.       
RBE β∗ δ∗∗ γa γe  
10 2.39 1.33 −1.12 −0.791 
35 2.76 0.413 −1.12 −0.797 
60 2.74 0.122 −1.13 −0.797 
80 2.62 0.0364 −1.13 −0.797 
100 2.46 0.000117 −1.13 −0.797 
Sasaki 1.64 1.15 −1.11 −0.793 
*in Gy−1. 
**in Gy−2.  
Table B4 
Results of fitting a linear-quadratic model to leukemia absolute incidence to the 
atomic bomb data at attained age 60 years after exposure at age 41 years ap-
plying the EPICURE-AMFIT code to the atomic survivor data of dataset 3 with 
respect to organ averaged dose.        
RBE β∗ δ# γe γa s  
10 1.99 0.970 0.420 −1.45 −0.200 
35 2.12 0.342 0.412 −1.40 −0.207 
60 2.08 0.112 0.408 −1.38 −0.212 
80 1.99 0.0440 0.406 −1.38 −0.214 
100 1.88 0.0114 0.405 −1.37 −0.216 
Sasaki 1.39 0.874 0.418 −1.44 −0.201 
*in (10,000 PY Gy)−1,#in 10,000 PY−1 Gy−2.  
Table B5 
Variances of the dose response fit parameters (e.g., the β in Eq.(1)) for relative 
and absolute incidence for solid cancer and leukemia at attained age 60 years 
after exposure at age 41 years applying the EPICURE-AMFIT code to the atomic 
survivor data of dataset 2 and 3.          
Solid cancer Leukemia    
RBE ERR β∗ EAR β∗∗ ERR β∗ ERR δ# EAR β∗∗ EAR δ## 
10 0.00242 6.76 0.967 0.273 0.462 0.172 
35 0.00152 4.27 0.745 0.0721 0.312 0.0471 
60 0.00103 2.92 0.569 0.0243 0.224 0.0159 
80 0.000788 2.25 0.463 0.0117 0.178 0.00762 
100 0.000622 1.78 0.380 0.00625 0.145 0.00404 
Sasaki 0.00182 5.11 0.621 0.159 0.318 0.102 
*in Gy−1, ## in Gy−2,** in (10,000 PY Gy)−1,## in 10,000 PY−1 Gy−2.  
Table B6 
Results of fitting a linear dose response model to solid cancer incidence to the 
atomic bomb data at attained age 70 years after exposure at age 30 years ap-
plying the EPICURE-AMFIT code to the atomic survivor data of dataset 1 with 
respect to weighted colon dose. Note: the results for ERR are from a re-fit of the 
model that is unadjusted for smoking from Table 5 of Grant et al. (2017) and 
the corresponding EAR model, not given by Grant et al. (2017), was published 
by Walsh et al. (2019b).       
Risk β γa γe s  
ERR 0.502 −1.57 −0.213 0.286 
EAR 53.3* 2.35 −0.320 0.139 
*in (10,000 PY Gy)−1.  
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4.6. Uncertainties 
The epidemiological data from the A-bomb survivors LSS are asso-
ciated with large errors. In this study the uncertainties of the LSS fit 
parameters from the different excess risk models are included using 
Monte Carlo simulations. Nevertheless, there are additional un-
certainties which can have an impact on the risk calculations. An ex-
ample of this is the fixed neutron RBE of 10 or the use of survival curves 
in the cancer risk calculation. Additionally, it has to be noted that the A- 
bomb survivors were exposed to γ-rays and neutrons. The models used 
to calculate the cancer risk in this study are based on these 
epidemiological data, but astronauts are mainly exposed to protons and 
heavy ions (GCR). The uncertain biological effectiveness of these par-
ticles and the different dose-rate of the GCR lead to additional un-
certainties, which must be accounted for in future work by applying a 
detailed dosimetric model to obtain the actual organ doses that are 
required for the risk analysis presented here. 
5. Conclusion 
The risk assessment methods LAR and REIC can both be applied to 
calculate space radiation induced cancer incidence risks based on 
models fitted to the most recent epidemiological data of A-bomb sur-
vivors. Nevertheless, one has to be aware that both methods are based 
on uncertain quantities such as survival curves and that REIC includes 
deterministic radiation induced non-cancer mortality risks, modelled 
based on the data of the general population, which may lead to an 
underestimation of the risks for astronauts. Additionally, a neutron RBE 
higher than 10 has a large impact on LAR and REIC and reduces the risk 
up to almost 50%. Including an EAR baseline scaling also increases the 
risks by 0.4%–8.1% for the space missions considered here, but further 
work is required in order to fully evaluate the advantages and dis-
advantages of applying this type of scaling. Using an EAR model instead 
of an equally weighted excess risk model can decrease the risks by 
0.4%–4.1% if no EAR baseline scaling is applied. If EAR baseline scaling 
is included, the calculated risks with the EAR- and the equally weighted 
model, as well as the risks calculated with the ERR model are almost 
identical and only small differences in their uncertainties are visible. 
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Table B7 
Results of fitting a linear quadratic dose response model to leukemia incidence to 
the atomic bomb data at attained age 70 years after exposure at age 30 years 
applying the EPICURE-AMFIT code to the atomic survivor data for dataset 3 
with respect to weighted RBM dose.         
Risk β δ γa γe swoman sman  
ERR 0.790 0.950 −1.09 −0.808   
EAR 1.06* 1.09⁎⁎ −1.48 0.412 −0.421 0 
*in (10,000 PY Gy)−1. 
**in 10,000 PY−1 Gy−2.  
Table B8 
Resulting covariance matrix for the ERR fit parameters from fitting a linear dose 
response model to solid cancer incidence to the atomic bomb data at attained age 
70 years after exposure at age 30 years applying the EPICURE-AMFIT code to 
the atomic survivor data of dataset 1 with respect to weighted colon dose.       
ERR cov β∗ γa γe s  
β∗ 0.00191 0.00282 0.00105 −0.000275 
γa 0.00282 0.0557 −0.00500 0.00163 
γe 0.00105 −0.00500 0.00261 −0.000309 
s −0.000275 0.00163 −0.000309 0.00345 
*in Gy−1.  
Table B9 
Resulting covariance matrix for the EAR fit parameters from fitting a linear dose 
response model to solid cancer incidence to the atomic bomb data at attained age 
70 years after exposure at age 30 years applying the EPICURE-AMFIT code to 
the atomic survivor data of dataset 1 with respect to weighted colon dose.       
EAR cov β∗ γa γe s  
β∗ 22.8 0.290 0.116 −0.113 
γa 0.290 0.0440 −0.00465 −0.00236 
γe 0.116 −0.00465 0.00259 −0.000132 
s −0.113 −0.00236 −0.000132 0.00387 
*in (10,000 PY Gy)−1.  
Table B10 
Resulting covariance matrix for the ERR fit parameters from fitting a linear 
quadratic dose response model to leukemia incidence to the atomic bomb data at 
attained age 70 years after exposure at age 30 years applying the EPICURE- 
AMFIT code to the atomic survivor data of dataset 3 with respect to weighted 
RBM dose.       
ERR cov β∗ δ∗∗ γa γe  
β∗ 0.218 −0.0555 0.00466 0.0287 
δ∗∗ −0.0555 0.123 0.0396 0.0242 
γa 0.00466 0.0396 0.197 −0.0555 
γe 0.0287 0.0242 −0.0555 0.0671 
*in Gy−1. 
**in Gy−2.  
Table B11 
Resulting covariance matrix for the EAR fit parameters from fitting a linear 
quadratic dose response model to leukemia incidence to the atomic bomb data at 
attained age 70 years after exposure at age 30 years applying the EPICURE- 
AMFIT code to the atomic survivor data of dataset 3 with respect to weighted 
RBM dose. For males the column and row with the gender parameter s can be 
neglected.        
EAR cov β∗ δ∗∗ γa γe s  
β∗ 0.302 −0.0746 0.0820 −0.0204 −0.0393 
δ∗∗ −0.0746 0.175 0.0545 −0.0114 −0.0273 
γa 0.0821 0.0545 0.112 −0.0288 −0.00620 
γe −0.0204 −0.0114 −0.0288 0.0116 0.00162 
s −0.0393 −0.0273 −0.00620 0.00162 0.0551 
*in (10,000 PY Gy)−1. 
**in 10,000 PY−1 Gy−2.  
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Appendix A 
ERR and EAR risk models based on dataset 2 and 3 
The ERR and EAR models applied to calculate REIC and LAR based on dataset 2 have the same structure as the models in Eq. (1), but the 
calculations are centered around an exposed age e of 41 years and an attained age a of 60 years. Therefore, different modifying functions are used. 
For solid cancer: 
= +µ e a s
e a






s e a (A1) 
where - is used for males and + for females. The fit parameters γe, γa and s are gender-averaged. For leukemia dataset 3 and the models from Eqs. (3) 
to (4) are used and with the different centring the corresponding modifying functions are: 
= +µ e a log
a e a
( , ) exp
19
log
60L e a1 (A2)  
= +µ e a s
e a





*exp( )L e a2 (A3)  
The fit parameters γe and γa are gender-averaged while s is only given for women and set to 0 for men. 
Appendix B 
Here the fit parameters and the corresponding covariance matrices resulting from fitting different models to data of the LSS for different neutron 
RBEs are shown. 
Appendix C 
Here the analogue figures to Figs. 2–4 for women are shown.  
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